Phase 1 Trial Assessing Stem Cell Therapy Recruiting Alzheimer’s Patients in Florida

Phase 1 Trial Assessing Stem Cell Therapy Recruiting Alzheimer’s Patients in Florida
A Phase 1 trial to evaluate the safety and effectiveness of Longeveron’s allogeneic mesenchymal stem cells (LMSCs) in patients with Alzheimer's disease is currently looking for participants, the biopharmaceutical company announced. Eligible participants must be between 50 and 80 years old, with a confirmed diagnosis of Alzheimer's disease in accordance with established criteria from the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association. Additionally, participants are required to have an identified adult caregiver. The randomized, double-blinded trial (NCT02600130) will take place in the U.S. at three centers in South Florida, two of them with open recruitment — Brain Matters Research in Delray Beach and the University of Miami Miller School of Medicine in Miami — and Miami Jewish Health Systems, which is not yet recruiting. Information on enrollment is available on the trial’s official page.
Researchers are aiming to recruit 30 participants who will be randomized to one of three groups — low-dose LMSCs, high-dose LMSCs, or placebo (control).
Participants in the low-dose LMSCs gro
Subscribe or to access all post and page content.



    A concern is the cost of these therapies, which is a real issue considering the extent of the population affected and the age of the patients. Also, that by year 2050 over 75% of the Alzheimer’s cases will occur in Asia and Latin America, raises questions about the capacity of those countries to afford high cost therapies. Perhaps it would be useful if efforts to develop preventive methods, like vaccines, would continue, but this time using a rational and sound approach, rather than the past failed strategies of the past.

Leave a Comment

Your email address will not be published. Required fields are marked *